Impact of the definition of time to event endpoint on randomized clinical trials results in oncology (datecan-2): an analysis of 9 pancreatic cancer trials

被引：0
|
作者：
Pam, A. [1 ]
Vernerey, D. [1 ]
Baron, B. [2 ]
Chauffert, B. [3 ]
Louvet, C. [4 ]
Wagener, J. [5 ]
Levi, F. [6 ,7 ]
Hans, S. [8 ]
Trouilloud, I. [9 ]
Jan, J. [10 ]
Van Laethem, J. L. [11 ]
Taieb, J. [9 ]
Haustermans, K. [12 ]
Dahan, L. [13 ]
Dureux, M. [14 ]
Lutz, M. [15 ]
Bellera, C. [16 ]
Gourgou, S. [17 ,18 ]
Anota, A. [1 ]
Bonnetain, F. [1 ]
机构：
[1] CHU Besancon, Doubs, F-25030 Besancon, France
[2] EORTC Data Ctr, Brussels, Belgium
[3] Anticanc Ctr GF Leclerc, Dept Oncol, Dijon, France
[4] Inst Mutualiste Montsouris, Dept Oncol, Paris, France
[5] UMC Nijmegen, Nijmegen, Netherlands
[6] Hop Paul Brousse, Villejuif, France
[7] INSERM, Villejuif, France
[8] Univ Hosp Rotterdam Dijikzigt, Rotterdam, Netherlands
[9] Georges Pompidou European Hosp, Dept Gastroenterol & Digest Oncol, Paris, France
[10] Univ Rotterdam Hosp, Rotterdam, Netherlands
[11] Erasme Univ Hosp, Medicosug Dept Gastroenerol, B-1070 Brussels, Belgium
[12] Univ Hosp Gasthuisberg, Leuven, Leuven, Belgium
[13] Univ Mediterranean, Timone Hosp, Hosp Publ Assistance Marseille, Marseille, France
[14] Inst Gustave Roussy, Gastrointestinal Unit, Villejuif, France
[15] Univ Ulm, D-89069 Ulm, Germany
[16] Inst Bergonie, Ctr Comprehens Canc, Clin & Epidemiol Res Unit, Bordeaux, France
[17] Inst Canc Montpellier, Ctr Comprehens Canc, Montpellier, France
[18] Data Ctr Canc Clin Trials, CTD INCa, Montpellier, France
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)31292-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2376
引用
收藏
页码：S462 / S462
页数：1
相关论文
共 50 条
  • [1] Guidelines for time-to-event endpoint definitions in randomized cancer trials for sarcomas and GIST: Results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
    Bellera, C.
    Ouali, M.
    Penel, N.
    Litiere, S.
    Casali, P.
    Bonvalot, S.
    Nielsen, O. S.
    Delannes, M.
    Mathoulin-Pelissier, S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S881 - S881
  • [2] INTERNATIONAL EXPERTS' CONSENSUS FOR THE DEFINITION OF TIME TO EVENT ENDPOINTS IN CLINICAL TRIALS (DATECAN PROJECT): RESULTS FOR PANCREATIC CANCER
    Bonnetain, Franck
    Dousseau, Adelaide
    Bert, Bonsing
    Bengt, Glimelius
    Haustermans, Karin
    Conroy, Thierry
    Van Laethem, Jean Luc
    Labianca, Roberto
    Macarulla, Teresa
    Tabernero, Josep
    Lutz, Manfred
    Neoptolemos, John P.
    De Gramont, Aimery
    Collette, Laurence
    ANNALS OF ONCOLOGY, 2012, 23 : 5 - 5
  • [3] International experts' panel for the development of guidelines for the definition of time to event endpoints in clinical trials (DATECAN project): Results for pancreatic cancer.
    Bonnetain, Franck
    Doussau, Adelaide
    Mathoulin-Pelissier, Simone
    Bonsing, Bert A.
    Glimelius, Bengt
    Haustermans, Karin
    Conroy, Thierry
    Van Laethem, Jean-Luc
    Labianca, Roberto
    Macarulla, Teresa
    Mauer, Murielle E.
    Lutz, Manfred P.
    Tabernero, Josep
    De Gramont, Aimery
    Hammel, Pascal
    Aust, Daniela Ellen
    Ducreux, Michel
    Taieb, Julien
    Neoptolemos, John P.
    Collette, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN projectaEuro
    Kramar, A.
    Negrier, S.
    Sylvester, R.
    Joniau, S.
    Mulders, P.
    Powles, T.
    Bex, A.
    Bonnetain, F.
    Bossi, A.
    Bracarda, S.
    Bukowski, R.
    Catto, J.
    Choueiri, T. K.
    Crabb, S.
    Eisen, T.
    El Demery, M.
    Fitzpatrick, J.
    Flamand, V.
    Goebell, P. J.
    Gravis, G.
    Houede, N.
    Jacqmin, D.
    Kaplan, R.
    Malavaud, B.
    Massard, C.
    Melichar, B.
    Mourey, L.
    Nathan, P.
    Pasquier, D.
    Porta, C.
    Pouessel, D.
    Quinn, D.
    Ravaud, A.
    Rolland, F.
    Schmidinger, M.
    Tombal, B.
    Tosi, D.
    Vauleon, E.
    Volpe, A.
    Wolter, P.
    Escudier, B.
    Filleron, T.
    ANNALS OF ONCOLOGY, 2015, 26 (12) : 2392 - 2398
  • [5] Guidelines for time-to-event endpoints' definitions in cancer randomized controlled trials (RCTs) for breast cancer - results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
    Gourgou-Bourgade, S.
    Dabakuyo-Yonli, S.
    Cameron, D.
    Cardoso, F.
    Poortmans, P.
    Asselain, B.
    Azria, D.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S441 - S442
  • [6] Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
    Gourgou-Bourgade, S.
    Cameron, D.
    Poortmans, P.
    Asselain, B.
    Azria, D.
    Cardoso, F.
    A'Hern, R.
    Bliss, J.
    Bogaerts, J.
    Bonnefoi, H.
    Brain, E.
    Cardoso, M. J.
    Chibaudel, B.
    Coleman, R.
    Cufer, T.
    Dal Lago, L.
    Dalenc, F.
    De Azambuja, E.
    Debled, M.
    Delaloge, S.
    Filleron, T.
    Gligorov, J.
    Gutowski, M.
    Jacot, W.
    Kirkove, C.
    MacGrogan, G.
    Michiels, S.
    Negreiros, I.
    Offersen, B. V.
    Llorca, F. Penault
    Pruneri, G.
    Roche, H.
    Russell, N. S.
    Schmitt, F.
    Servent, V.
    Thuerlimann, B.
    Untch, M.
    van der Hage, J. A.
    van Tienhoven, G.
    Wildiers, H.
    Yarnold, J.
    Bonnetain, F.
    Mathoulin-Pelissier, S.
    Bellera, C.
    Dabakuyo-Yonli, T. S.
    ANNALS OF ONCOLOGY, 2015, 26 (05) : 873 - 879
  • [7] Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials)
    Bonnetain, Franck
    Bonsing, Bert
    Conroy, Thierry
    Dousseau, Adelaide
    Glimelius, Bengt
    Haustermans, Karin
    Lacaine, Francois
    Van Laethem, Jean Luc
    Aparicio, Thomas
    Aust, Daniela
    Bassi, Claudio
    Berger, Virginie
    Chamorey, Emmanuel
    Chibaudel, Benoist
    Dahan, Laeticia
    De Gramont, Aimery
    Delpero, Jean Robert
    Dervenis, Christos
    Ducreux, Michel
    Gal, Jocelyn
    Gerber, Erich
    Ghaneh, Paula
    Hammel, Pascal
    Hendlisz, Alain
    Jooste, Valerie
    Labianca, Roberto
    Latouche, Aurelien
    Lutz, Manfred
    Macarulla, Teresa
    Malka, David
    Mauer, Muriel
    Mitry, Emmanuel
    Neoptolemos, John
    Pessaux, Patrick
    Sauvanet, Alain
    Tabernero, Josep
    Taieb, Julien
    van Tienhoven, Geertjan
    Gourgou-Bourgade, Sophie
    Bellera, Carine
    Mathoulin-Pelissier, Simone
    Collette, Laurence
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (17) : 2983 - 2993
  • [8] Guidelines for the definitions of time-to-event endpoints in randomized clinical trials: Results of the datecan project for breast group
    Gourgou-Bourgade, S.
    Dabakuyo-Yonli, S.
    Cameron, D.
    Cardoso, F.
    Poortmans, P.
    Asselain, B.
    Azria, D.
    CANCER RESEARCH, 2013, 73
  • [9] Guidelines for the definitions of time-to-event endpoints in randomized clinical trials: Results of the DATECAN Project for Breast Group
    Gourgou, Sophie
    Dabakuyo, Tienhan Sandrine
    Asselain, Bernard
    Azria, David
    Cameron, David A.
    Cardoso, Fatima
    Poortmans, Philip M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Guidelines for the definitions of time-to-event endpoints in randomized clinical trials: Results of the DATECAN Project for Sarcomas and GISTs
    Bellera, Carine A.
    Ouali, Monia
    Penel, Nicolas
    Bonvalot, Sylvie
    Casali, Paolo Giovanni
    Delannes, Martine
    Nielsen, Ole Steen
    Mathoulin-Pelissier, Simone
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345